Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer

December 15, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / December 15, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) On December 7, the Company received a letter from the US Food and Drug Administration (FDA) removing a partial clinical hold on Nascent's proprietary monoclonal antibody Pritumumab. This allows Nascent to commence Phase I Human Clinical Trials, effective immediately. Nascent CEO Sean Carrick stated, "The approval by the FDA is a major milestone in...

Read more

ThinkGenetic Announces Integration of Innovative Diagnostic Aid in Takeda Pilot Awareness Initiative

December 15, 2020 6:00 AM

BOSTON, MA / ACCESSWIRE / December 15, 2020 / ​ThinkGenetic, Inc. is set to launch three disease-specific versions of the diagnostic aid, SymptomMatcher™ for upcoming pilot awareness initiatives by global biopharmaceutical leader, Takeda Pharmaceutical Company Limited. Six pilots, which will be released publicly in 2021, create a tailored online interactive experience to help individuals determine if their health signs and symptoms...

Read more

Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

December 14, 2020 11:15 AM

FRAMINGHAM, MA / ACCESSWIRE / December 14, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today the closing of its previously announced registered direct offering with several institutional and accredited investors for...

Read more

Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient

December 14, 2020 8:30 AM

Final Patient in First-in-Human Study Shows Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / December 14, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the eleventh and final VenoValve patient in HJLI's first-in-human, clinical study has successfully reached the one-year milestone. Patient 11's chronic...

Read more

Applied UV Expands Executive Leadership Team with Appointment of Rhonda Wallen as Vice President of Product Marketing and Corporate Development

December 14, 2020 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / December 14, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultraviolet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, today announced that Rhonda A. Wallen has joined the Company as Vice President of Product Marketing & Corporate Development. As...

Read more

Mosaic ImmunoEngineering Inc. Provides an Overview of Development Plans for Advancing Its Lead Immuno-Oncology Product Candidate MI-O-101

December 14, 2020 8:00 AM

-Preclinical Data Published in Peer Reviewed Journals Support Advancing the Program into Human Clinical Trials- -Company Plans to Initiate Discussions with Regulatory Agencies in Early 2021 to Review Its Strategy for IND or Equivalent Filing- -Data Generated in Companion Animals with Naturally Occurring Tumors Support Potential Veterinary Applications- NOVATO, CA / ACCESSWIRE / December 14, 2020 / Mosaic ImmunoEngineering Inc., (the...

Read more

IN STOCK: COVID-19 Coronavirus 'Rapid Test Kits' For Immediate Delivery

December 11, 2020 8:10 AM

CHEYENNE, WY / ACCESSWIRE / December 11, 2020 / MJ Biotech, Inc. (OTCQB:MJTV), is pleased to announce that given the global COVID-19 (coronavirus) healthcare crisis and the nationwide acute shortage of testing supplies, MJ BIOTECH INC. has entered the Professional medical testing sector and has IN STOCK FOR IMMEDIATE DELIVERY Emergency Use Authorized COVID-19 "Coronavirus" IgG/IgM Rapid Test Kits. These Kits are very much...

Read more

Ron Kilgarlin of American Screening LLC - On Offering Comprehensive Choice of Urine and Saliva Drug Tests

December 10, 2020 6:15 PM

SHREVEPORT, LA / ACCESSWIRE / December 10, 2020 / American Screening LLC alongside its founder, Ron Kilgarlin, has been supporting efforts to combat substance abuse and addiction for nearly 17 years by providing a vast array of drug testing products and striving to offer the best possible prices without compromising on quality. This has helped the Shreveport, Louisiana-based company become an ISO13485 contract manufacturer and one of the leading...

Read more

DECN Secures Exclusive Distributor Agreement With a German Based Company for the Distribution of Genviro! Covid-19 :10 Saliva Testing Kits and Meters in 18 EU Countries, Norway and the UK

December 10, 2020 9:15 AM

WITH THIS DEAL THE TOTAL NUMBER OF COUNTRIES COVERED BY DECN INTERNATIONAL AGREEMENTS NOW APPROACHES 50 WITH MORE ANTICIPATED LOS ANGELES, CA / ACCESSWIRE / December 10, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., today announced it has...

Read more

Applied UV Appoints Sales Veteran Robert Berger as Vice President of Global Sales

December 10, 2020 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / December 10, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultraviolet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, today announced that Robert Berger joined the Company as Vice-President Global Sales on December 7, 2020. As part of the executive...

Read more

Hancock Jaffe to Provide VenoValve and CoreoGraft Updates at Ladenburg Thalmann R&D Showcase Webinar on December 16, 2020

December 10, 2020 8:30 AM

VenoValve and CoreoGraft Primary Investigators to Present at Webinar IRVINE, CA / ACCESSWIRE / December 10, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that on Wednesday, December 16, 2020, at 1:00 Eastern time, Ladenburg Thalmann will host an R&D Showcase Webinar for Hancock Jaffe at which HJLI will provide updates on the VenoValve and...

Read more

Heat Biologics Provides Business Update

December 10, 2020 8:00 AM

DURHAM, NC / ACCESSWIRE / December 10, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-7. The reverse stock split will take effect as of...

Read more

Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets

December 10, 2020 6:50 AM

Asset Sale in Preparation for Potential US National Securities Exchange Listing KELOWNA, BC / ACCESSWIRE / December 10, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has closed the sale of its non-pharmaceutical THC-related assets ("the Assets") held within Lexaria Canpharm ULC, a Lexaria wholly-owned...

Read more

Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

December 10, 2020 12:50 AM

FRAMINGHAM, MA / ACCESSWIRE / December 10, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that it has entered into a securities purchase agreement with several institutional and accredited investors providing for...

Read more

Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology

December 9, 2020 8:35 AM

Xenetic leverages its proprietary drug delivery platform, PolyXen, through partnerships with biotechnology and pharmaceutical companies to improve the half-life and other pharmacological properties of next-generation biologic drugs Epolong, a polysialylated form of recombinant human erythropoietin that leverages PolyXen, has been shown to be effective and generally well tolerated in Pharmsynthez-conducted trial as a treatment for anemia in...

Read more

Dyadic to Interview with FOX Business Network on Wednesday December 9, 2020

December 9, 2020 8:30 AM

JUPITER, FL / ACCESSWIRE / December 9, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more

Babe Ruth League Partners With Binovi Technologies in Order to Provide Sport Vision Training to Its Youth Athletes

December 9, 2020 3:05 AM

TORONTO, ON / ACCESSWIRE / December 9, 2020 / Binovi Technologies Corp. (Binovi) (TSXV:VISN)(OTCQB:BNVIF)(FRA:2EYA) is proud to announce a partnership with the Babe Ruth League, one of the largest youth baseball and softball organizations in the United States, serving more than 1,000,000 players in over 11,000 leagues across the country. Through the partnership, Binovi becomes the Official Provider of Health Programming for Babe Ruth...

Read more

Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment

December 8, 2020 8:30 AM

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / December 8, 2020 / December 2, 2020 / Pascal Biosciences Inc. (TSXV:PAS)(OTC PINK:BIMUF) ("Pascal" or the "Company") and SōRSE Technology Corporation ("SōRSE") have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the cannabinoid PAS-393 towards clinical testing against cancer. "This progress is very promising...

Read more

GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations

December 8, 2020 8:00 AM

LAS VEGAS / ACCESSWIRE / December 8, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,857,107 entitled "Cannabinoid-Containing Complex Mixtures for the Treatment of Mast-Cell-Associated or Basophil-Mediated Inflammatory Disorders" today, Dec. 8, 2020. This U.S. patent is assigned to GBS Global Biopharma (GBS), Inc., GB Sciences' Canadian...

Read more

Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD

December 8, 2020 8:00 AM

Havn Life will collaborate on future clinical studies with Heroic Hearts Project to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD). VANCOUVER, BC / ACCESSWIRE / December 8, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the...

Read more